Overview

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
Phase:
Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Relugolix